HC Wainwright Reaffirms Buy Rating for HTG Molecular Diagnostics Inc (HTGM)
HTG Molecular Diagnostics Inc (NASDAQ:HTGM)‘s stock had its “buy” rating reaffirmed by equities researchers at HC Wainwright in a research note issued to investors on Thursday. They presently have a $5.00 target price on the stock. HC Wainwright’s price target indicates a potential upside of 54.80% from the stock’s previous close.
Several other research analysts have also issued reports on the company. Rodman & Renshaw started coverage on HTG Molecular Diagnostics in a research report on Monday, August 22nd. They set a “buy” rating and a $5.00 target price on the stock. Zacks Investment Research raised HTG Molecular Diagnostics from a “sell” rating to a “hold” rating in a research report on Wednesday, July 13th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $5.25.
Shares of HTG Molecular Diagnostics (NASDAQ:HTGM) traded up 4.19% during mid-day trading on Thursday, reaching $3.23. The company had a trading volume of 7,105,654 shares. The company’s market capitalization is $22.77 million. HTG Molecular Diagnostics has a 52 week low of $2.03 and a 52 week high of $6.22. The stock has a 50 day moving average of $2.46 and a 200-day moving average of $2.65.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/13/hc-wainwright-reaffirms-buy-rating-for-htg-molecular-diagnostics-inc-htgm.html
HTG Molecular Diagnostics (NASDAQ:HTGM) last announced its earnings results on Tuesday, August 9th. The company reported ($0.98) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.95) by $0.03. On average, analysts expect that HTG Molecular Diagnostics will post ($3.58) earnings per share for the current fiscal year.
About HTG Molecular Diagnostics
HTG Molecular Diagnostics, Inc is a commercial-stage company that develops and markets a technology platform to facilitate the routine use of complex molecular profiling. The Company’s HTG Edge and HTG EdgeSeq platforms, consisting of instrumentation, consumables and software analytics, are used in sample profiling applications, including tumor profiling, molecular diagnostic testing and biomarker development.
Receive News & Ratings for HTG Molecular Diagnostics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HTG Molecular Diagnostics Inc and related companies with MarketBeat.com's FREE daily email newsletter.